Corporate Governance | Regeneron Pharmaceuticals Inc.

Date	Name	Title	Filing	Type	Shares Traded	Price	Total Held
Feb 12, 2014	YANCOPOULOS GEORGE Director, President Regeneron Laboratori	Director, President Regeneron Laboratori	Form 4	Open market or private sale of non-derivative or derivative security	15,816	$318.52	1,137,192
May 07, 2013	YANCOPOULOS GEORGE Director, President Regeneron Laboratori	Director, President Regeneron Laboratori	Form 4	Open market or private sale of non-derivative or derivative security	47,876	$262.43	1,145,062
Feb 12, 2014	YANCOPOULOS GEORGE Director, President Regeneron Laboratori	Director, President Regeneron Laboratori	Form 4	Open market or private sale of non-derivative or derivative security	4,322	$317.82	1,153,008
Feb 11, 2014	YANCOPOULOS GEORGE Director, President Regeneron Laboratori	Director, President Regeneron Laboratori	Form 4	Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3	94,756	$314.31	1,157,330
May 07, 2013	YANCOPOULOS GEORGE Director, President Regeneron Laboratori	Director, President Regeneron Laboratori	Form 4	Open market or private sale of non-derivative or derivative security	13,457	$261.66	1,192,938
May 06, 2013	YANCOPOULOS GEORGE Director, President Regeneron Laboratori	Director, President Regeneron Laboratori	Form 4	Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3	93,644	$260.44	1,206,395
Feb 11, 2014	YANCOPOULOS GEORGE Director, President Regeneron Laboratori	Director, President Regeneron Laboratori	Form 4	Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3	5,720	$314.31	1,252,086
Feb 11, 2014	YANCOPOULOS GEORGE Director, President Regeneron Laboratori	Director, President Regeneron Laboratori	Form 4	Exercise or conversion of derivative security exempted pursuant to Rule 16b-3	189,463	$9.49	1,257,806
Dec 14, 2012	YANCOPOULOS GEORGE Director, EVP CSO Pres Regen Res Labs	Director, EVP CSO Pres Regen Res Labs	Form 4	Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3	38,391	$179.13	1,294,650
Dec 17, 2012	YANCOPOULOS GEORGE Director, EVP CSO Pres Regen Res Labs	Director, EVP CSO Pres Regen Res Labs	Form 4	Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3	47	$179.13	1,294,708

* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.

Investors & Media